Endocyte, Inc. Announces Late-Breaking Abstract Presentation At The European Society For Medical Oncology (ESMO) Conference
WEST LAFAYETTE, Ind., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented at the European Society for Medical Oncology (ESMO) Conference on Saturday, Sept. 27, in Madrid, Spain.
| Presentation is as follows: | |
| Session Type: | Late Breaking Abstract, Proffered Paper Session, LBA40_PR |
| Session Title: | NSCLC, metastatic 1 |
| Title: | TARGET: A randomized, phase II trial comparing vintafolide versus vintafolide plus |
| docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive | |
| non-small cell lung cancer (NSCLC) patients | |
| When: | Saturday, Sept. 27, 4:00 – 4:15 p.m. CEST (10:00 – 10:15a.m. EDT) |
| Location: | Madrid Auditorium, Hall 6 |
| Additional posters are as follows: | |
| Session Type: | Poster # 481P |
| Session Title: | Developmental therapeutics |
| Title: | Phase 1 dose-escalation study of the folic acid-tubulysin small-molecule drug |
| conjugate EC1456 in patients (pts) with advanced solid tumors | |
| When: | Saturday, Sept. 27, 12:45 – 1:45 p.m. CEST (6:45 – 7:45a.m. EDT) |
| Location: | Poster Area, Hall 8 |
| Session Type: | Poster # 894P |
| Session Title: | Gynaecological cancer |
| Title: | PRECEDENT Subset Analysis: Safety and Disease control with Vintafolide |
| Monotherapy Following Discontinuation of Pegylated Liposomal Doxorubicin (PLD) | |
| When: | Saturday, Sept. 27, 12:45 – 1:45 p.m. CEST (6:45 – 7:45a.m. EDT) |
| Location: | Poster Area, Hall 8 |
About Vintafolide (EC145)
Vintafolide is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine hydrazide (DAVLBH). Vintafolide is designed to target the chemotherapy agent to rapidly growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian cancer and non-small cell lung cancer. The randomized TARGET Phase 2 study of vintafolide in NSCLC has completed enrollment (ClinicalTrials.gov Identifier: NCT01577654).
About EC1456
EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
Endocyte Forward-Looking Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the company's expectations for seeking regulatory approval and commercial launch of its products, including any conditional marketing authorization from the EMA, initiation of future clinical trials, and expectations for the receipt of milestones, royalties or other profits from the company's partnership with Merck. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, unavailability of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company's product candidates, the goals of its development activities, estimates of the potential markets for its product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected financial results. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com 